John K. C. Lim

Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ.

Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Part of McKesson Corp., US Oncology Research LLC specializes in conducting oncology clinical trials. With a network of experienced investigators and clinical staff, the American company manages around 400 active trials across approximately 60 research sites and over 165 locations. Over the past two decades, the physicians in the research network have enrolled more than 85,000 patients in over 1,600 trials and have contributed to over 100 FDA-approved cancer therapies. The company is supported by McKesson Corporation and offers specialty practice management solutions, medication adherence plans, and pharmaceutical distribution and supply chain solutions.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.